ピューロマイシン
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2014/06/14 11:14:41」(JST)
[Wiki en表示]
Puromycin |
|
IUPAC name
3'-deoxy-N,N-dimethyl-3'-[(O-methyl-L-tyrosyl)amino]adenosine
|
Identifiers |
CAS number |
53-79-2 N |
PubChem |
439530 |
ChemSpider |
388623 Y |
DrugBank |
DB08437 |
KEGG |
D05653 Y |
MeSH |
Puromycin |
ChEBI |
CHEBI:17939 Y |
ChEMBL |
CHEMBL469912 N |
Jmol-3D images |
Image 1 |
-
O=C(N[C@@H]3[C@H](O[C@@H](n2cnc1c2ncnc1N(C)C)[C@@H]3O)CO)[C@@H](N)Cc4ccc(OC)cc4
|
-
InChI=1S/C22H29N7O5/c1-28(2)19-17-20(25-10-24-19)29(11-26-17)22-18(31)16(15(9-30)34-22)27-21(32)14(23)8-12-4-6-13(33-3)7-5-12/h4-7,10-11,14-16,18,22,30-31H,8-9,23H2,1-3H3,(H,27,32)/t14-,15+,16+,18+,22+/m0/s1 Y
Key: RXWNCPJZOCPEPQ-NVWDDTSBSA-N Y
InChI=1/C22H29N7O5/c1-28(2)19-17-20(25-10-24-19)29(11-26-17)22-18(31)16(15(9-30)34-22)27-21(32)14(23)8-12-4-6-13(33-3)7-5-12/h4-7,10-11,14-16,18,22,30-31H,8-9,23H2,1-3H3,(H,27,32)/t14-,15+,16+,18+,22+/m0/s1
Key: RXWNCPJZOCPEPQ-NVWDDTSBBO
|
Properties |
Molecular formula |
C22H29N7O5 |
Molar mass |
471.51 g mol−1 |
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa) |
N (verify) (what is: Y/N?) |
Infobox references |
|
|
Puromycin is an antibiotic that is a protein synthesis inhibitor by inhibiting translation.
Contents
- 1 Inhibition of translation
- 2 Peptidase Inhibitor
- 3 Cell culture
- 4 Selection of Escherichia coli
- 5 References
- 6 External links
Inhibition of translation
Puromycin is an aminonucleoside antibiotic, derived from the Streptomyces alboniger bacterium,[1] that causes premature chain termination during translation taking place in the ribosome. Part of the molecule resembles the 3' end of the aminoacylated tRNA. It enters the A site and transfers to the growing chain, causing the formation of a puromycylated nascent chain and premature chain release.[2] The exact mechanism of action is unknown at this time but the 3' position contains an amide linkage instead of the normal ester linkage of tRNA. That makes the molecule much more resistant to hydrolysis and stops the ribosome.
Puromycin is not selective for either prokaryotes or eukaryotes.
Also of note, puromycin is critical in mRNA display. In this reaction, a puromycin molecule is chemically attached to the end of an mRNA template, which is then translated into protein. The puromycin can then form a covalent link to the growing peptide chain allowing the mRNA to be physically linked to its translational product.
Antibodies that recognize puromycylated nascent chains can also be used to purify newly synthesized polypeptides[3] and to visualize the distribution of actively translating ribosomes by immunofluorescence.[4]
Peptidase Inhibitor
Puromycin is a reversible inhibitor of dipeptidyl-peptidase II (serine peptidase) and cytosol alanyl aminopeptidase (metallopeptidase).[5][6] The mechanism of inhibition is not well understood, however puromycin can be used to distinguish between aminopeptidase M (active) and cytosol alanyl aminopeptidase (inhibited by puromycin).
Cell culture
Puromycin is used in cell biology as selective agent in cell culture systems. It is toxic to prokaryotic and eukaryotic cells. Resistance to puromycin is conferred by the Pac gene encoding a puromycin N-acetyl-transferase (PAC) that was found in a Streptomyces producer strain. Puromycin is soluble in water (50 mg/ml) as colorless solution at 10 mg/ml. Puromycin is stable for one year as solution when stored at -20 °C. The recommended dose as a selection agent in cell cultures is within a range of 1-10 μg/ml, although it can be toxic to eukaryotic cells at concentrations as low as 1 μg/ml. Puromycin acts quickly and can kill up to 99% of nonresistant cells within 2 days.
Selection of Escherichia coli
Puromycin is poorly active on E. coli. Puromycin-resistant transformants are selected in LB agar medium supplemented with 125 µg/ml of puromycin. But use of puromycin for E. coli selection requires precise pH adjustment and also depends on which strain is selected. For hassle–free selection and optimum results the use of special modified puromycin is possible. Plates containing puromycin are stable for 1 month when stored at 4 °C.
References
- ^ Puromycin from Fermentek
- ^ Pestka, S. (1971). "Inhibitors of ribosome functions". Annu. Rev. Microbiol. 25: 487–562. doi:10.1146/annurev.mi.25.100171.002415. PMID 4949424.
- ^ Eggers, D.K., Welch, W.J., and Hansen W.J. (1997). "Complexes between nascent polypeptides and their molecular chaperones in the cytosol of mammalian cells". Mol Biol Cell 8 (8): 1559–1573. doi:10.1091/mbc.8.8.1559. PMC 276176. PMID 9285825.
- ^ Starck, S.R., Green, H.M., Alberola-Ila, J. and Roberts R.W. (2004). "A general approach to detect protein expression in vivo using fluorescent puromycin conjugates". Chem. Biol. 11 (7): 999–1008. doi:10.1016/j.chembiol.2004.05.011. PMID 15271358.
- ^ Dando, P.M, Young, N.E & Barrett, A.J (1997). Biomed Health Res 13: 88–95.
- ^ McDonald, J. K., Reilly, T. J., Zeitman, B.B., and Ellis, S. (1968). J Bio Chem 243: 2028–2037.
External links
- The MEROPS online database for peptidases and their inhibitors: Puromycin
Antibacterials: protein synthesis inhibitors (J01A, J01B, J01F, J01G, QJ01XQ)
|
|
30S |
Aminoglycosides
(initiation inhibitors) |
-mycin (Streptomyces) |
- Streptomycin#
- Dihydrostreptomycin
- Neomycin#
- Framycetin
- Paromomycin
- Ribostamycin
- Kanamycin#
- Amikacin
- Arbekacin
- Bekanamycin
- Dibekacin
- Tobramycin
- Spectinomycin#
- Hygromycin B
|
|
-micin (Micromonospora) |
- Gentamicin#
- Netilmicin
- Sisomicin
- Isepamicin
|
|
|
Tetracycline antibiotics
(tRNA binding) |
Tetracyclines |
- Doxycycline#
- Chlortetracycline
- Clomocycline
- Demeclocycline
- Lymecycline
- Meclocycline
- Metacycline
- Minocycline
- Oxytetracycline
- Penimepicycline
- Rolitetracycline
- Tetracycline
|
|
Glycylcyclines |
|
|
|
|
50S |
Oxazolidinone
(initiation inhibitors) |
- Eperezolid
- Linezolid
- Posizolid
- Radezolid
- Ranbezolid
- Sutezolid
- Tedizolid
|
|
Peptidyl transferase |
Amphenicols |
- Chloramphenicol#
- Azidamfenicol
- Thiamphenicol
- Florfenicol
|
|
Pleuromutilins |
- Retapamulin
- Tiamulin
- Valnemulin
|
|
|
MLS (transpeptidation/translocation) |
Macrolides |
- Azithromycin#
- Clarithromycin
- Dirithromycin
- Erythromycin#
- Flurithromycin
- Josamycin
- Midecamycin
- Miocamycin
- Oleandomycin
- Rokitamycin
- Roxithromycin
- Spiramycin
- Troleandomycin
- Tylosin
- Ketolides
- Telithromycin
- Cethromycin
- Solithromycin†
|
|
Lincosamides |
- Clindamycin#
- Lincomycin
- Pirlimycin
|
|
Streptogramins |
- Pristinamycin
- Quinupristin/dalfopristin
- Virginiamycin
|
|
|
|
EF-G |
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
gr+f/gr+a (t)/gr-p (c)/gr-o
|
drug (J1p, w, n, m, vacc)
|
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Slit diaphragm protein Neph1 and it's signaling: a novel therapeutic target for protection of podocytes against glomerular injury.
- Arif E1, Rathore YS, Kumari B, Ashish F, Wong HN, Holzman LB, Nihalani D.Author information 1University of Pennsylvania, United States;AbstractPodocytes are specialized epithelial cells that are critical components of the glomerular filtration barrier and their dysfunction leads to proteinuria and renal failure. Therefore, preserving podocyte function is therapeutically significant. In this study, we identified Neph1 signaling as a therapeutic target which upon inhibition prevented podocyte damage from a glomerular injury inducing agent PAN (puromycin aminonucleosinde). To specifically inhibit Neph1 signaling we used a protein transduction approach, where the cytoplasmic domain of Neph1 (Neph1CD) tagged with a protein transduction domain TAT (trans-activator of transcription) was transduced in cultured podocytes prior to treatment with PAN. The PAN induced Neph1 phosphorylation was significantly reduced in Neph1CD transduced cells; in addition, these cells were resistant to PAN-induced cytoskeletal damage. The biochemical analysis using subfractionation studies showed that unlike control cells, Neph1 was retained in the lipid raft fractions in the transduced cells following treatment with PAN, indicating that transduction of Neph1CD in podocytes prevented PAN induced mislocalization of Neph1. In accordance, the immunofluorescence analysis further suggested that Neph1CD transduced cells had increased ability to retain endogenous Neph1 at the membrane in response to PAN-induced injury. Similar results were obtained when Angiotensin was used as an injury-inducing agent. Consistent with these observations, maintaining high levels of Neph1 at the membrane using a podocyte cell line overexpressing chimeric Neph1 increased the ability of podocytes to resist, PAN-induced injury and PAN-induced albumin leakage. Using a zebrafish in vivo PAN and adriamycin injury models, we further demonstrated the ability of transduced Neph1CD to preserve glomerular function. Collectively, these results support the conclusion that inhibiting Neph1 signaling is therapeutically significant in preventing podocyte damage from glomerular injury.
- The Journal of biological chemistry.J Biol Chem.2014 Feb 19. [Epub ahead of print]
- Podocytes are specialized epithelial cells that are critical components of the glomerular filtration barrier and their dysfunction leads to proteinuria and renal failure. Therefore, preserving podocyte function is therapeutically significant. In this study, we identified Neph1 signaling as a therape
- PMID 24554715
- Mechanism of the Photoinduced Uncaging Reaction of Puromycin Protected by a 6-Nitroveratryloxycarbonyl Group.
- Kohl-Landgraf J, Buhr F, Lefrancois D, Mewes JM, Schwalbe H, Dreuw A, Wachtveitl JL.AbstractThe cleavage of a photolabile nitroveratryloxycarbonyl protecting group (NVOC), which is widely used as caging group, was studied by femtosecond-transient absorption spectroscopy in the visible and infrared spectral range and by flash-photolysis experiments on the longer time scale. Based on quantum chemical calculations it is shown that directly after excitation triplet absorption dominates the transient spectrum which is not part of the reactive pathway and that the molecules following the triplet pathway are trapped in a non-reactive triplet state. By contrast photolysis proceeds from the singlet manifold. Therefore trapping in the triplet state lowers the quantum yield of the process for this compound compared to other ortho-nitrobenzyl protecting groups. With our integrated approach of time-resolved UV and IR measurements and calculations we can characterize the entire uncaging mechanism and identify the most relevant intermediate states along the reaction pathway. The final uncaging is accomplished within 32 µs.
- Journal of the American Chemical Society.J Am Chem Soc.2014 Feb 11. [Epub ahead of print]
- The cleavage of a photolabile nitroveratryloxycarbonyl protecting group (NVOC), which is widely used as caging group, was studied by femtosecond-transient absorption spectroscopy in the visible and infrared spectral range and by flash-photolysis experiments on the longer time scale. Based on quantum
- PMID 24517286
- Probing the Leucyl/Phenylalanyl tRNA Protein Transferase Active Site with tRNA Substrate Analogues.
- Fung AW, Ebhardt HA, Krishnakumar KS, Moore J, Xu Z, Strazewski P, Fahlman RP1.Author information 1474 Medical Sciences Building. Department of Biochemistry. University of Alberta. Edmonton, Alberta, T6G 2H7, Canada. rfahlman@ualberta.ca.AbstractAminoacyl-tRNA protein transferases post-translationally conjugate an amino acid from an aminoacyl-tRNA onto the N-terminus of a target polypeptide. The eubacterial aminoacyl-tRNA protein transferase, L/F transferase, utilizes both leucyl-tRNALeu and phenylalanyl-tRNAPhe as substrates. X-ray crystal structures with substrate analogues, the minimal substrate phenylalanyl adenosine (rA-Phe) and inhibitor puromycin, have been used to characterize tRNA recognition by L/F transferase. However analyses of these two X-ray crystal structures reveal significant differences in binding. Through structural analyses, mutagenesis, and enzymatic activity assays, we rationalize and demonstrate that the substrate analogues bind to L/F transferase with similar binding affinities using a series of different interactions by the various chemical groups of the analogues. Our data also demonstrates that enlarging the hydrophobic pocket of L/F transferase selectively enhances puromycin inhibition and may aid in the development of improved inhibitors for this class of enzymes.
- Protein and peptide letters.Protein Pept Lett.2014 Feb 11. [Epub ahead of print]
- Aminoacyl-tRNA protein transferases post-translationally conjugate an amino acid from an aminoacyl-tRNA onto the N-terminus of a target polypeptide. The eubacterial aminoacyl-tRNA protein transferase, L/F transferase, utilizes both leucyl-tRNALeu and phenylalanyl-tRNAPhe as substrates. X-ray crystal
- PMID 24521222
Japanese Journal
- SPECIFIC INHIBITORS OF PUROMYCIN-SENSITIVE AMINOPEPTIDASE WITH A 3-(HALOGENATED PHENYL)-2,4(1H,3H)-QUINAZOLINEDIONE SKELETON (Dedicated to Professor Dr. Ei-ichi Negishi on the occasion of his 77th birthday)
- Matsumoto Yotaro,Noguchi-Yachide Tomomi,Nakamura Masaharu [他]
- Heterocycles : an international journal for reviews and communications in heterocyclic chemistry 86(2), 1449-1463, 2012-12-31
- NAID 40019534016
- Effect of Pamamycin-607 on Secondary Metabolite Production by Streptomyces spp.
- Hashimoto Makoto,Katsura Hirotaka,Kato Risako [他],KAWAIDE Hiroshi,NATSUME Masahiro
- Bioscience, biotechnology, and biochemistry 75(9), 1722-1726, 2011-09-23
- … Exposure to 6.6 μM pamamycin-607 stimulated by 2.7 fold the puromycin production by <I>Streptomyces alboniger</I> …
- NAID 10029757098
- Microintaglio Printing of Biomolecules and Its Application to In situ Production of Messenger Ribonucleic Acid Display Microarray
- Biyani Manish,Osawa Terutsune,Nemoto Naoto [他],Ichiki Takanori
- Applied physics express 4(4), 047001-047001-3, 2011-04-25
- … Furthermore, one-step conversion from an mRNA microarray into an mRNA-protein fusion microarray was performed by simultaneous cell-free protein synthesis and fusion reaction using a puromycin-labeled oligonucleotide linker. …
- NAID 150000001203
Related Links
- Puromycin is an aminonucleoside antibiotic produced by the bacterium Streptomyces alboniger. It inhibits protein synthesis by disrupting peptide transfer on ribosomes causing premature chain termination during translation. It is a ...
- Puromycin is an aminonucleoside antibiotic produced by the bacterium Streptomyces alboniger. It inhibits protein synthesis by disrupting peptide transfer on ribosomes causing premature chain termination during translation. It is a ...
Related Pictures
★リンクテーブル★
[★]
[★]
- 英
- puromycin PM
- ラ
- puromycinum
- 同
- ピュロマイシン
- 関
- 抗菌薬
[★]
ピューロマイシンアミノヌクレオシド
- 関
- aminonucleoside